Amendia Inc. said yesterday that it acquired the minimally-invasive transforaminal lumbar interbody fusion system assets from SpineSelect.
The system assets purchased by Amendia include 2 product families – the Marquise MIS channel system and the Turbo MIS TLIF system, the Marietta, Ga.-based company said.
“The addition of SpineSelect’s MITLIF system allows Amendia to offer another superior solution for both patients and surgeons. We look forward to building relationships with SpineSelect’s current customers and distribution groups, while expanding our product portfolio with novel technologies,” Amendia CEO Jeff Smith said in a press release.
Amendia gained a total of 20 spinal technology patents from SpineSelect, the company said.
“The team at SpineSelect has worked hard to develop truly differentiated technology, covered by 20 patents, that helps surgeons perform less invasive lumbar fusion procedures and achieve better patient outcomes. We are thrilled that Amendia shares the same commitment to delivering innovative, outcomes-driven technology. I am amazed by the amount of innovation occurring at Amendia, and we look forward to joining this dynamic and emerging leader in the spine industry,” SpineSelect president John Eckman said in prepared remarks.
Last April, Amendia sold its anterior cervical fusion distraction pin business to Illinois-based Medline Industries, but did not disclose the terms of the deal.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.